Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | RNASEL | Q05823 | 7/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736455 | 0.95 | P2RX3 (0.77) | P2RX3RNASEL | |
| SCHEMBL18087247 | 0.87 | P2RX3 (0.68) | P2RX3RNASEL | |
| SCHEMBL16727889 | 0.87 | P2RX3 (0.68) | P2RX3RNASEL | |
| SCHEMBL22381588 | 0.84 | RNASEL (0.66) | RNASELADORA1 | |
| SCHEMBL29547343 | 0.84 | RNASEL (0.65) | RNASELADORA1 | |
| SCHEMBL18521787 | 0.84 | RNASEL (0.77) | RNASEL | |
| SCHEMBL29452474 | 0.84 | P2RX3 (0.65) | P2RX3RNASELADORA1 | |
| SCHEMBL24160912 | 0.83 | P2RX3 (0.85) | P2RX3RNASELADORA1 | |
| SCHEMBL18258283 | 0.83 | P2RX3 (0.85) | P2RX3RNASELADORA1 | |
| SCHEMBL22399796 | 0.83 | RNASEL (0.57) | P2RX3RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024197401-A1 | 1,3,4-THIADIAZOL-2-YL CARBOXAMIDE AND 1,3-THIAZOL-2-YL CARBOXAMIDE COMPOUNDS AND USES THEREOF AS INHIBITORS OF HUMAN POLYMERASE THETA | REPARE THERAPEUTICS INC. (CA) | 2024-10-03 | — | — | WO | claimed |
| CN-109324141-B | Characteristic fingerprint spectrum of guangdong or processed products thereof, and construction method and application thereof | 广州白云山中药饮片有限公司 | 2022-05-03 | — | — | CN | claimed |
| WO-2026100273-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, APPARATUS FOR PRODUCING USEFUL SUBSTANCE, AND ALGAE CONTAINING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | GILEAD SCIENCES, INC. | 2026-01-22 | — | — | US | disclosed |
| WO-2025226656-A1 | HEPATITIS B VIRUS MRNA VACCINES | MODERNATX, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4594316-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| CN-119811549-A | Analysis method for relationship between process impurities and degradation impurities based on big data analysis technology | 中国食品药品检定研究院 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064869-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12223181-B2 | Storage device and electronic device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-02-11 | — | — | US | disclosed |
| EP-4459415-A2 | OVERSHOOT-FREE FAST START-UP BANDGAP REFERENCE CIRCUIT, CHIP, AND ELECTRONIC DEVICE | Vanchip (Tianjin) Technology Co. Ltd (CN) | 2024-11-06 | — | — | EP | disclosed |
| EP-4114941-A2 | IMPROVED METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations VI, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11485784-B2 | Ranking system for immunogenic cancer-specific epitopes | ACT GENOMICS (IP) CO., LTD. (HK) | 2022-11-01 | — | — | US | disclosed |
| CN-112328000-B | Ultra-low quiescent current quick response circuit and device | 江苏清微智能科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022153481-A1 | POSTURE ESTIMATION APPARATUS, LEARNING MODEL GENERATION APPARATUS, METHOD, AND COMPUTER-READABLE RECORDINGMEDIUM | NEC CORPORATION (JP) | 2022-07-21 | — | — | WO | disclosed |
| CN-114566534-A | High-voltage element of switching power supply circuit and manufacturing method thereof | 立锜科技股份有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220157982-A1 | HIGH VOLTAGE DEVICE OF SWITCHING POWER SUPPLY CIRCUIT AND MANUFACTURING METHOD THEREOF | RICHTEK TECHNOLOGY CORPORATION (TW) | 2022-05-19 | — | — | US | disclosed |
| CN-109324141-B | Characteristic fingerprint spectrum of guangdong or processed products thereof, and construction method and application thereof | 广州白云山中药饮片有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113985957-B | Overshoot-free quick-start band gap reference circuit, chip and electronic equipment | 唯捷创芯(天津)电子技术股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-113985957-A | Overshoot-free quick-start band gap reference circuit, chip and electronic equipment | 唯捷创芯(天津)电子技术股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | POLK, POLQ, POLB | P2RX3 3385/4885RNASEL 2277/4885ADORA1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.